Top Story

Pemetrexed plus cisplatin active in advanced, recurrent cervical carcinoma

August 21, 2014

The combination of pemetrexed and cisplatin appeared safe and effective in women with advanced, persistent or recurrent carcinoma of the cervix, according to results of a phase 2 trial.

“This combination should be further developed in the treatment of cervical cancer,” David Scott Miller, MD, professor of obstetrics and gynecology at UT Southwestern Medical Center, and colleagues wrote. “Given that it may be less toxic than and as active as cisplatin plus paclitaxel, and that it can be combined with bevacizumab (Avastin, Genentech), comparison of cisplatin–pemetrexed plus bevacizumab with cisplatin–paclitaxel plus bevacizumab would be appropriate.”

In the Journals

Higher UV radiation linked to increased prevalence of nonmelanoma skin cancers

August 20, 2014
Higher mean daily UV radiation was associated with increased non-melanoma skin cancer incidence rates, according to study findings.Researchers systematically reviewed 40…
figure In the Journals

Regular transfusions reduced stroke recurrence in pediatric sickle cell anemia

August 20, 2014
Children with sickle cell anemia who underwent regular blood-transfusion therapy experienced fewer recurrences of cerebral infarct, according to results of a…
figure In the Journals

High-mitotic rate melanoma linked to patient, tumor characteristics

August 20, 2014
Melanomas with higher mitotic rates occurred more frequently in men and in individuals aged older than 70 years, according to results of a cross-sectional study.These…
More News Headlines »
CME

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

8/16/2014
Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
figure

Docetaxel plus ADT improved OS in metastatic prostate cancer

June 24, 2014
CHICAGO — Donald L. Trump, MD, FACP, president and CEO at Roswell Park Cancer Institute and HemOnc Today
More »

MPN Updates

This electronic newsletter is sponsored by Incyte Corp. through a third-party independent grant.

1/8/2014
As the standards of care for patients with myeloproliferative neoplasms (MPNs) continue to evolve, physicians must stay…
More »